Involvement of Multiple Transport Systems in the Disposition of an Active Metabolite of a Prodrug-type New Quinolone Antibiotic, Prulifloxacin

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 6, 2003, Pages 381-389

  Yagi, Yukihiro ^a   Shibutani, Sachiyo ^a   Hodoshima, Naoko ^a   Ishiwata, Kazuya ^a   Okudaira, Noriko ^a   Li, Qing ^b   Sai, Yoshimichi ^b   Kato, Yukio ^b   Tsuji, Akira ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

biliary excretion; brain; p glycoprotein; pharmacokinetics; prulifloxacin

Indexed keywords

EID: 3042812719     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.381     Document Type: Article

References (22)

1. Nakashima, M., Uematsu, T. and Kosuge, K.: Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. Japan. J. Chemother., 44 (S-1): 180-206 (1996).
2. Murakami, K., Tanimura, H., Ishimoto, K., Uchiyama, K., Iwakura, S., Aoki, Y., Oka, S., Donishi, H., Yamamoto, S., Ichimiya, G., Kobayashi, Y., Iwahashi, H., Mishima, H., Fukunaga, H., Hayashido, M., Hotta, T., Hashimoto, M. and Sakamoto, Y.: Excretion into bile and gallbladder tissue level of a new quinolone, NM441 and its clinical efficacy on surgical infections.Japan. J. Chemother., 44 (S-1): 462-470 (1996).
3. Hori, S. and Shimada, J.: Effect of NM441 and its active form on GABA receptor binding. Japan. J. Chemother., 44 (S-1): 97-101 (1996).
4. Ukai, Y., Yamazaki, A., Kurosawa, C., Ishima, T., Yoshikuni, Y. and Kimura, K.: Convulsant effects of NM441, a prodrug type antibacterial agent of the quinolone class. Japan. J. Chemother., 44 (S-1): 102-112 (1996).
5. Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T. and Hori, R.: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther., 263: 840-845 (1992).
6. Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka, N., Komano, T. and Hori, R.: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem., 267: 24248-24252 (1992).
7. Matsuda, M., Okuyama, Y., Morino, A. and Ozaki, M.: Assay methods for NM441 in body fluids. Japan. J. Chemother., 44 (S-1): 147-154 (1996).
8. Murata, M., Tamai, I., Sai, Y., Nagata, O., Kato, H., Sugiyama, Y. and Tsuji, A: Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab. Dispos., 26: 1113-1119 (1998).
9. Sasabe, H., Tsuji, A. and Sugiyama, Y.: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J. Pharmacol. Exp. Ther., 284: 1033-1039 (1998).
10. Schinkel, A. H. and Mayer, U., Wagenaar, E., Mol, C. A., van Deemter, L., Smit, J. J., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, J. M., Fibbe, W. E. and Borst, P.: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A., 94: 4028-4033 (1997).
11. Böhme, M., Büchler, M., Müller, M. and Keppler, D.: Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. PEBS, 333: 193-196 (1993).
12. Chen, Z. S., Kawabe, T., Ono, M., Aoki, S., Sumizawa, T., Furukawa, T., Uchiumi, T., Wada, M., Kuwano, M. and Akiyama, S.: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol. Pharmacol., 56: 1219-1228 (1999).
13. Yamaguchi, H., Yano, I., Saito, H. and Inui, K.: Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J. Pharmacol. Exp. Ther., 300: 1063-1069 (2002).
14. Shitara Y., Itoh, T., Sato, H., Li, A. P. and Sugiyama, Y.: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporine A. J. Pharmacol. Exp. Ther., 304: 610-616 (2003).
15. Tsuji, A., Sato, H., Kume, Y., Tamai, I., Okezaki, E., Nagata, O. and Kato, H.: Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob. Agents Chemother., 32: 190-194 (1988).
16. Tsuji, A., Sato, H., Okezaki, E., Nagata, O. and Kato, H.: Effect of anti-inflammatory agent fenbufen on the quinolone-induced inhibition of γ-aminobutyric acid binding to receptor sites in rat brain membranes in vitro. Biochem. Pharmacol., 37: 4408-4411 (1988).
17. Tamai, I. and Tsuji, A.: Transporter-mediated permeation of drugs across the blood-brain barrier. J. Pharm. Sci., 89: 1371-1388 (2000).
18. Ooie, T., Suzuki, H., Terasaki, T. and Sugiyama, Y.: Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs. J. Pharmacol. Exp. Ther., 278: 590-596 (1996).
19. Murata, M., Tamai, I., Kato, H., Nagata, O. and Tsuji, A.: Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J. Pharmacol. Exp. Ther., 290: 51-57 (1999).
20. Ooie, T., Terasaki, T., Suzuki, H. and Sugiyama, Y.: Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J. Pharmacol. Exp. Ther., 283: 293-304 (1997).
21. Tamai, I., Yamashita, J., Kido, Y., Ohnari, A., Sai, Y., Shima, Y., Naruhashi, K., Koizumi, S. and Tsuji, A.: Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J. Pharmacol. Exp. Ther., 295: 146-152 (2000).
22. Okumura, Y., Momota, K. and Morino, A.: Pharmacokinetics of prulifloxacin. 1st communication absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Arzneimittelfor-shung, 47: 276-284 (1997).